GE HealthCare Technologies Inc.: Beat — EPS $1.34, Revenue $5.51B
Earnings BeatQ3 2026 · Pre-market
Did GE HealthCare Technologies Inc. (GEHC) beat earnings today?
Yes, GE HealthCare Technologies Inc. (GEHC) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+11.67% surprise
$1.34Actual
Expected: $1.20
vs. year ago +25.1%
Total Revenue+3.05% surprise
$5.51BActual
Expected: $5.35B
vs. year ago +7.2%
Released Oct 28 · 6:20 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $5.51B | $5.14B | +7.2% |
| Revenue detail — reported lines | |||
| └─Sales of products | $3.60B | $3.38B | +6.7% |
| └─Sales of services | $1.91B | $1.77B | +8.0% |
| └─AIS revenues | $3.87B | $3.65B | +6.1% |
| └─PDx revenues | $846.00M | $749.00M | +13.0% |
| └─PCS revenues | $793.00M | $731.00M | +8.5% |
| └─Other revenues | $2.00M | $15.00M | -89.4% |
| Net Income | $615.00M | $446.00M | +37.9% |
| GAAP Basic EPS | $1.36 | $0.98 | +38.8% |
| GAAP Diluted EPS | $1.36 | $0.98 | +38.8% |
| Adjusted EPS | $1.34 | $1.07 | +25.1% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY2026 Outlook |
|---|---|---|
| Organic Revenue Growth | — | ~4.0% (prev. 3.0% - 4.0%) |
| Adjusted EBIT Margin | — | 15.5% - 15.7% (prev. 15.4% - 15.7%) |
| Adjusted EPS | — | $4.95 - $5.05 (prev. $4.80 - $5.00) |
| Free Cash Flow | — | $1.6B+ (prev. ~$1.6B) |
Business Highlights
- ➤Jeannette Bankes will leave Patient Care Solutions for a publicly traded company CEO role.
- ➤Neal Sandy becomes Patient Care Solutions President and CEO on November 16, 2026.
- ➤Plans to acquire SOFIE Biosciences for $945M in cash, subject to closing conditions.
- ➤SOFIE acquisition establishes a U.S. final-mile PET radiopharmaceutical supply footprint.
- ➤Expanded general imaging ultrasound portfolio with LOGIQ Focus.
- ➤Expanded research collaboration exploring generative AI for personalized radiation therapy.
- ➤Announced CareIntellect for operations to optimize health-system resources and expand care access.
- ➤StarGuide GX 4D SPECT/CT is 510(k) pending with the U.S. FDA.
- ➤Photonova Spectra gained CE Mark, expanding international access.
- ➤Unveiled next-generation Vivid cardiovascular ultrasound portfolio for advanced cardiac imaging.
- ➤Expanded breast imaging portfolio with Invenia ABUS Prime and ABUS StreamVue launch.
Management Commentary
Peter Arduini, President and CEO
“We delivered strong top-line growth and margin expansion across all segments, and robust EPS growth in the third quarter. This reflects our teams’ commercial execution, disciplined operational focus enabled by Heartbeat, and continued customer adoption of our innovations. With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.”